| |
With three foreign trade zones, including the largest non-contiguous zone in the U.S., bioscience firms in Puerto Rico profit from affordable international trade. It's not what's next, it's where. Puerto Rico.
|
|
Today’s Big NewsMay 6, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now.
|
|
| By Angus Liu Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities. |
|
|
|
By Gabrielle Masson The Novo Nordisk Foundation, Wellcome and the Bill & Melinda Gates Foundation have inked a $300 million R&D initiative focused in part on infectious diseases and antimicrobial resistance. |
By Conor Hale The watch’s sensor and software marked the first digital health product to be qualified under the agency’s Medical Device Development Tools program. |
By Andrea Park Neurocrine Biosciences, maker of the first drug approved by the FDA to treat tardive dyskinesia, continues to throw its weight behind efforts to improve screening, monitoring and general awareness of the neurological disorder. |
|
Tuesday, May 16, 2024 | 10 ET / 7am PT Clinical trials are shifting towards sustainability and efficiency, necessitating industry leaders to embrace innovative provisioned device solutions. This webinar reveals new approaches reshaping the clinical trial supply chain to mitigate carbon footprints and revolutionize device lifecycle management. Explore how proactive sustainability in device management can differentiate leading companies in life sciences innovation.
|
|
By Fraiser Kansteiner With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward. |
By Nick Paul Taylor GlycoMimetics CEO Harout Semerjian told investors in March that phase 3 blood cancer results could “fundamentally impact our company's trajectory.” And the CEO was absolutely right, just not in the way he hoped. |
By Kevin Dunleavy Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer fueled the opioid crisis by failing to act on suspicious opioid orders. |
By Max Bayer Italian pharma Chiesi is betting almost $500 million to jointly commercialize Gossamer's late-stage Winrevair rival. The asset is currently enrolling patients in a phase 3 study. |
By Eric Sagonowsky Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead candidate failed to meet its primary endpoint in a phase 2 trial. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now.
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
